These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 28242553)

  • 1. Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhang Q; Zhu G; Zhang Z; Zhi Y; Zhang L; Mao T; Zhou X; Chen Y; Lu T; Tang W
    Eur J Med Chem; 2017 Apr; 130():86-106. PubMed ID: 28242553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
    Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance.
    Zhang Y; Wang L; Zhang Q; Zhu G; Zhang Z; Zhou X; Chen Y; Lu T; Tang W
    J Chem Inf Model; 2017 Jun; 57(6):1439-1452. PubMed ID: 28485964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
    Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
    Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.
    Wang L; Zhang Y; Zhang Q; Zhu G; Zhang Z; Duan C; Lu T; Tang W
    Eur J Med Chem; 2019 Feb; 163():243-255. PubMed ID: 30529543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
    Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
    Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
    Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
    Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
    Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.
    Cheng H; Chang Y; Zhang L; Luo J; Tu Z; Lu X; Zhang Q; Lu J; Ren X; Ding K
    J Med Chem; 2014 Mar; 57(6):2692-703. PubMed ID: 24588073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.
    Okaniwa M; Hirose M; Arita T; Yabuki M; Nakamura A; Takagi T; Kawamoto T; Uchiyama N; Sumita A; Tsutsumi S; Tottori T; Inui Y; Sang BC; Yano J; Aertgeerts K; Yoshida S; Ishikawa T
    J Med Chem; 2013 Aug; 56(16):6478-94. PubMed ID: 23906342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
    Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
    Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
    Yu H; Jung Y; Kim H; Lee J; Oh CH; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3805-8. PubMed ID: 20466542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
    Zhan W; Li Y; Huang W; Zhao Y; Yao Z; Yu S; Yuan S; Jiang F; Yao S; Li S
    Bioorg Med Chem; 2012 Jul; 20(14):4323-9. PubMed ID: 22721924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
    Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
    Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
    Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
    J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.
    Lu B; Cao H; Cao J; Huang S; Hu Q; Liu D; Shen R; Shen X; Tao W; Wan H; Wang D; Yan Y; Yang L; Zhang J; Zhang L; Zhang L; Zhang M
    Bioorg Med Chem Lett; 2016 Feb; 26(3):819-823. PubMed ID: 26739779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.